Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) have received a consensus recommendation of “Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $11.50.
Several research analysts have recently issued reports on ACRS shares. Guggenheim started coverage on shares of Aclaris Therapeutics in a research note on Tuesday, May 5th. They issued a “buy” rating and a $12.00 target price on the stock. Oppenheimer started coverage on shares of Aclaris Therapeutics in a research note on Thursday, April 16th. They set an “outperform” rating and a $10.00 price target for the company. UBS Group set a $10.00 price objective on shares of Aclaris Therapeutics in a report on Thursday, April 16th. Wedbush raised their price objective on shares of Aclaris Therapeutics from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Wednesday, April 29th. Finally, Wall Street Zen raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th.
Get Our Latest Research Report on ACRS
Hedge Funds Weigh In On Aclaris Therapeutics
Aclaris Therapeutics Trading Down 0.2%
NASDAQ:ACRS opened at $5.90 on Tuesday. The stock has a market capitalization of $824.94 million, a P/E ratio of -10.17 and a beta of 0.78. Aclaris Therapeutics has a 1 year low of $1.58 and a 1 year high of $6.51. The firm has a 50 day moving average of $5.16 and a 200-day moving average of $4.35.
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative return on equity of 61.65% and a negative net margin of 921.50%.The business had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $1.38 million. As a group, analysts forecast that Aclaris Therapeutics will post -0.64 EPS for the current fiscal year.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.
Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.
Featured Articles
- Five stocks we like better than Aclaris Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
